Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 8100 participants.

Also called NCT07507500

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 8,100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07507500
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Ireland, Latvia, Norway, Poland, Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07507500. Randomized; single masking; primary purpose treatment. Start 2026-09-02 (actual); primary completion 2029-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
Acronym
STREAMLINE
Condition
Myocardial Infarction (MI)
Intervention (Drug)
Prasugrel
Intervention (Drug)
Ticagrelor
Lead sponsor
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (class: other)
Collaborator
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (class: other)

Record details

Record id
cardio:ct-nct07507500
Content hash
252c6c6436b72cf629babc11bc7146a388f9af68208770d8e8d4bf1c5120359a